Xiamen Humanity Hospital
Oncology treatment in China typically costs from $19,000 to $51,300 for a full course of care. Final expenses depend on the cancer stage, the specific technology used, and the length of hospital stay. International patients often find 50-85% savings compared to prices in the US.
Typical Oncology Costs in China
Major oncology centers are located in Beijing, Shanghai, and Guangzhou. While facilities in tier-1 cities like Beijing often charge more than regional hospitals, they provide access to English-speaking staff. Consult with a specialist to get an accurate price for your specific diagnosis.
| China | Turkey | Austria | |
| Thyroid resection | from $8,200 | from $3,500 | from $10,000 |
| Stomach cancer surgery | from $18,500 | from $12,000 | from $30,000 |
| Removal of spinal cord tumor | from $19,500 | from $9,650 | from $50,000 |
| Removal of liver cancer | from $21,500 | from $10,800 | from $40,000 |
| Removal of colon cancer | from $17,500 | from $14,400 | from $20,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Oncology treatment upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Oncology treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Oncology treatment journey.
Dr. Luan Tianyan, MD, is Head of Oncology. He was recruited to Hainan Province as a high-level talent. He is a visiting scholar at the Dana-Farber Cancer Institute (USA). He is also Director of the Clinical Research Office at Bozheng Hengda International Hospital. He serves on the standing committees of the Clinical Research Management Committee (Southern Oncology Clinical Research Association), the Immunotherapy Committee (Hainan Provincial Anti-Cancer Association), and the Hainan Province Drug Research Committee.
He has more than 20 years of oncology practice. He provides individualized, comprehensive care for gastrointestinal tumors, lung cancer, and breast cancer. He focuses on pain management, palliative care, and psychological support in advanced cancer. He also works on the clinical use and study of tumor immunotherapy, including personalized mRNA vaccines and CAR-T therapy. He develops and applies proprietary drugs and related technologies.
Dr. Zhang Yanjun is a chief radiation oncologist at Jinshazhou Hospital in Guangzhou. He oversees pediatric and adult cases with a focus on neuro-oncology and stereotactic radiotherapy. Dr. Zhang completed two international fellowships at prominent cancer centers in the United States. He sits on the Executive Committee of the World Association of Chinese Oncology Physicians.
Dr. Chen Binglai is a biological immunology expert (MD). He holds a PhD in Medicine from Central South University, with a focus on genetics and integrated TCM and Western medicine. He completed postdoctoral training at New York University and the University of Bologna. He is a visiting professor at Zhongshan Hospital, Fudan University.
He is affiliated with the Shanghai Pujiang Talent Program and the Yangpu District 3310 Talent Program. He leads the innovation project “Cancer Treatment Based on Cell Culture Technology,” supported by the Pujiang Program.
He has years of oncology practice and extensive experience in treating malignant tumors. His work focuses on the clinical use and research of CAR-T, NK cell, and stem cell therapies. He uses the Lecheng pilot program to advance clinical translation in China and to offer personalized treatment plans.
Nearly 10,000 cryosurgeries performed – Prof. Niu Lizhi leads Fuda Cancer Hospital's minimally invasive oncology program.
Written by Kateryna Zamkovska
Written by Anna Leonova
Written by Anna Shchur
Written by Kateryna Zamkovska
Written by Kateryna Zamkovska
Chinese cancer centers follow rigorous safety standards including Joint Commission International (JCI) accreditation and the Organisation of European Cancer Institutes (OECI) certifications. Top-tier facilities like Fuda Cancer Hospital and Yanda International Hospital maintain Class A Level III status. This represents the highest medical quality tier in China.
Bookimed Expert Insight: Our data shows a clear link between patient volume and specialized safety. Clinics like Jinshazhou Hospital serve 680,000+ patients annually. High-volume centers often invest more in internationally recognized radiotherapy technologies. They also tend to offer structured multilingual medical travel services to support foreign patients.
Patient Consensus: Patients note that top clinics provide high-tech equipment and specialized nursing care. Some suggest bringing a translator for detailed medical discussions to ensure all treatment steps are clear.
Chinese oncologists demonstrate international expertise through prestigious global memberships, specialized Western training, and clinical research. Leading specialists hold executive roles in organizations like the International Society of Cryosurgery. Many undergo fellowships at top-tier institutions in the United States or participate in global Phase I-IV drug trials.
Bookimed Expert Insight: Patient volume in China drives a unique level of procedural expertise. For example, Dr. Niu Lizhi at Fuda Cancer Hospital has performed nearly 10,000 cryosurgery procedures. This massive clinical exposure, combined with JCI-accredited environments at Yanda International, ensures that theoretical international training is backed by unmatched practical experience.
Patient Consensus: Patients note that top doctors are extremely knowledgeable and the facilities are high-tech. They value the ability to access specialized treatments, like cryoablation, while staying in rooms that feel like high-end hotels.
Recovery timelines for oncology in China vary by treatment type. Patients undergoing minimally invasive procedures like NanoKnife or cryosurgery often return to light activities within 3 to 7 days. Surgical cases usually require 2 to 4 weeks for basic mobility. International travel is typically safe 10 to 14 days post-surgery.
Bookimed Expert Insight: Data from high-volume centers like Yanda International Hospital and Fuda Cancer Hospital shows a preference for combining international protocols with traditional approaches. This hybrid model often focuses on rapid stabilization. Patients choosing minimally invasive therapies like NanoKnife frequently report shorter hospital stays. This allows for earlier discharge to local hotels compared to traditional open surgeries.
Patient Consensus: Patients note that arriving with a 2-week buffer for monitoring is practical. They emphasize that while some feel ready to fly in 48 hours after non-surgical therapy, staying for a week helps manage unexpected fever or fatigue.
International patients in China access oncology treatments like Chimeric Antigen Receptor T-cell (CAR-T) therapy, NanoKnife, and cryosurgery. JCI-accredited facilities in Guangzhou and Beijing provide precision radiotherapy and immunotherapy. These centres specialise in organ-preserving techniques for solid tumours and blood cancers.
Bookimed Expert Insight: China's oncology landscape is defined by its massive volume. Clinics like Fuda Cancer Hospital have treated over 30,000 international patients. This scale allows surgeons to perform rarer procedures like NanoKnife hundreds of times annually. For Australians, this frequent experience means doctors handle complex cases often seen less at home.
Patient Consensus: Patients note that Chinese clinics focus on organ preservation when other countries suggest removal. They appreciate the five-star room facilities. They also value medical staff who arrange translators to bridge communication gaps.
International oncology patients in China receive support through dedicated international departments. These teams bridge language and logistical gaps. Major centres like Fuda Cancer Hospital provide JCI-accredited care with multilingual services. Hospitals often assist with S2 medical visas and offer on-site interpreters for complex multidisciplinary team reviews.
Bookimed Expert Insight: Language support tiers vary significantly between public and private hospitals in Guangzhou and Beijing. Clinics with 4.5+ ratings, like Yanda International Hospital, typically combine international protocols with traditional Chinese medicine. These JCI-accredited facilities often provide bilingual paperwork. This is essential for patients returning to the Australian healthcare system.
Patient Consensus: Patients in China often note that native-speaking translators help communication during busy consultations. They suggest bringing translated medical records and hiring a local coordinator. This helps manage appointments, transport, and follow-up schedules comfortably.
International patients can access experimental cancer clinical trials in China if the trial design allows foreign enrolment. Many local registration trials restrict participation to Chinese citizens. However, Multi-Regional Clinical Trials (MRCTs) actively include global patients. Eligibility requires matching specific diagnostic protocols and securing an S-class medical visa.
Bookimed Expert Insight: A major advantage in China is the concentration of trial capabilities within high-volume tertiary hospitals. Xiamen Humanity Hospital manages 1,000,000 patients annually and is authorised for all drug trial phases. This volume creates a massive data pool. This often leads to faster trial progression compared to smaller Western centres.
Patient Consensus: Patients note that Chinese hospitals often offer hope when domestic treatments fail. They particularly highlight the modern equipment and five-star room facilities. Patients find that native-speaking translators help bridge the language gap. This helps doctors explain complex diagnoses in detail.
Australians seeking oncology care in China should focus on JCI-accredited facilities with international wings. Leading centres in Guangzhou and Beijing provide English-speaking coordination. They use precise therapies like NanoKnife and cryosurgery to treat complex, solid tumours.
Bookimed Expert Insight: Oncology patients often find that high-volume centres in Guangzhou specialise in organ-sparing techniques. Dr Niu Lizhi has performed nearly 10,000 cryosurgeries. This volume is rarely seen in single Australian centres. This vast clinical experience often allows doctors to treat cases considered inoperable elsewhere.
Patient consensus: Patients from Commonwealth countries highlight the modern equipment. They note that Chinese specialists often focus on saving organs rather than removal. The wards are often described as similar to five-star rooms with helpful staff. Dedicated translation support also helps to ease the journey.
Traditional Chinese Medicine (TCM) is fully integrated into oncology care in China through a dual-system framework. Hospitals such as Jinshazhou Hospital of Guangzhou University of Chinese Medicine use TCM as supportive therapy. It is used alongside chemotherapy and immunotherapy to manage side effects and bolster immune function.
Bookimed Expert Insight: Clinical data shows that the most effective integration occurs in university-affiliated hospitals. For example, Jinshazhou Hospital uses its link with Guangzhou University of Chinese Medicine to standardise herbal treatments. This helps prevent TCM from interfering with modern therapies like Keytruda or NanoKnife. Such treatments are common in these high-volume centres.
Patient Consensus: Patients in China describe TCM as a helpful way to manage side effects and improve energy. Many value having local translators and 5-star room facilities. These amenities support those receiving both modern immunotherapy and traditional herbal support.